Shmuel Yaccoby

High Impact

Professor

UAMS primary UA Little Rock

Also affiliated: St. Luke's-Roosevelt Hospital Center (2001); Howard Hughes Medical Institute (2001); Norwegian University of Science and Technology (2000); Cornell University (2001); University of Arkansas Medical Center (2016–2018); Cancer Research And Biostatistics (2006–2015); Myeloma UK (2017–2018); Winthrop Rockefeller Foundation (2013–2025); Millennium Engineering and Integration (United States) (2005); International Myeloma Foundation (2015); Arkansas Department of Agriculture (2015); Best Biotech (2009); Rockefeller University (2001)

Faculty Researcher

Internal Med, College of Medicine

46 h-index 199 pubs 8,170 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website UAMS TRI Profile

OverviewAI-generated summary

Shmuel Yaccoby's research focuses on understanding the molecular mechanisms underlying multiple myeloma and identifying potential therapeutic targets. His work investigates the complex interactions within the bone marrow microenvironment, particularly the roles of mesenchymal stem cells and their secreted factors in controlling myeloma cell growth, dormancy, and bone disease.

Recent publications from Yaccoby's laboratory have explored epigenomic alterations in oncogenes, the potential of PHF19 inhibition as a therapeutic strategy, and the expansion of EDNRA-expressing mesenchymal cells in myeloma progression. His group has also studied the impact of mesenchymal stem cell cytotherapy on osteoclastogenesis and myeloma-induced bone disease. Furthermore, his research has examined the effects of cyclin-dependent kinase inhibitors, such as dinaciclib, on homologous recombination and their synergistic potential with PARP inhibitors in multiple myeloma treatment. Yaccoby's work has been recognized through a high-impact researcher designation, supported by a publication record of 199 papers and over 8,000 citations, with an h-index of 46.

Metrics

h-index: 46
Publications: 199
Citations: 8,170

Selected Publications

Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice (2025)

Haematologica DOI OpenAlex
Induction of HMOX1 by mesenchymal stem cell cytotherapy inhibits osteoclastogenesis and myeloma‐induced bone disease (2025)

Clinical and Translational Medicine DOI OpenAlex
EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression (2023)

Cancers 7 citations DOI OpenAlex
Growth and dormancy control of myeloma cells by mesenchymal stem cells (2023)

Leukemia Research 6 citations DOI OpenAlex
Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers (2021)

Genome Research 25 citations DOI OpenAlex
PHF19 inhibition as a therapeutic target in multiple myeloma (2021)

Current Research in Translational Medicine 9 citations DOI OpenAlex
CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction (2020)

Blood DOI OpenAlex
Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers (2020)

bioRxiv (Cold Spring Harbor Laboratory) 2 citations DOI OpenAlex
The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma (2019)

Blood DOI OpenAlex
The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells (2019)

Blood DOI OpenAlex
Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma (2019)

Haematologica 60 citations DOI OpenAlex
Microhomology-mediated end joining drives complex rearrangements and over-expression of MYC and PVT1 in multiple myeloma (2019)

bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes (2018)

Blood 1 citation DOI OpenAlex
Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors (2018)

Blood DOI OpenAlex
Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes (2018)

British Journal of Haematology 22 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

Effect of TACI-lg and BAFFR-lg on primary myeloma growth in SCID-hu mice ZymoGenetics, Inc Principal Investigator
Effect of VELCADE on Myeloma Bone Disease and Tumor Progression in a SCID-rab model for Primary Lymphoma Millennium Pharmaceuticals, Inc. Principal Investigator
Inhibition of primary myeloma by Thrombospondin-1 Peptide Mimetic in vivo Abbott, Inc. Principal Investigator
DEAP Awards - S Yaccoby - UAMS VCRI - FY26 UAMS Division of Research and Innovation Principal Investigator
Anti-myeloma efficacy of PDACs/HPP Celgene Principal Investigator
Effect of BI-505 ICAM-1 antibody on growth of myeloma cells in vitro and in vivo BioInvent Principal Investigator
Role of SPRPs in the anti-myeloma response of osteoblasts Multiple Myeloma Research Foundation Principal Investigator
Study of Effect of VELCADE on Osteoblast Activity Millennium Pharmaceuticals, Inc. Principal Investigator